Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.

Get Updates in Your Inbox

Sign Up.  Stay Informed.

The Conversation

Something is Rotten in the State of Colorado

Something is Rotten in the State of Colorado

Last month, members of the Colorado General Assembly introduced a bill intended to lower prescription drug costs in the state. The legislation (Senate Bill 21-175) would create a Prescription Drug Affordability Review Board to set payment caps on drugs deemed to be...

read more
Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.

Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.

Comments on ICER's February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”.  Some of the concerns raised in the letter point out that the...

read more